论文部分内容阅读
目的探讨孤独症患儿听觉感觉门控电位P50的改变及随治疗的变化。方法 30例孤独症患儿在利司哌酮(0.5 mg,po,bid×20 wk)治疗前后应用美国Bravo脑电生理仪,采用条件刺激(S1)-测试刺激(S2)模式检测P50,并进行孤独症行为评定量表(ABC)和儿童期孤独症评定量表(CARS)评分,另设40名正常同龄儿童为正常对照组。结果孤独症组治疗后ABC评分和CARS评分均显著下降(P<0.01)。孤独症组治疗前与正常对照组相比,S1-P50波幅降低,S2-P50波幅增高,S1-S2的差值降低(均P<0.01);2组S1-P50和S2-P50的潜伏期无显著差异(P>0.05)。孤独症组治疗20 wk后与治疗前相比,S1-P50和S2-P50的潜伏期和波幅均无显著变化(P>0.05)。结论 P50变化可能是孤独症患儿所具有的特定生物学指标之一。
Objective To investigate the changes of auditory gating potentials P50 in children with autism and their changes with treatment. Methods Thirty children with autism were enrolled in this study. Bravo electroencephalography was performed before and after treatment with risperidone (0.5 mg, po, bid × 20 wk). P50 was detected by conditioned stimulation (S1) -test stimulus (S2) Autistic behavior assessment scale (ABC) and childhood autism Rating Scale (CARS) were scored. Forty normal children of the same age were selected as normal control group. Results After treatment, ABC score and CARS score of autism group were significantly decreased (P <0.01). Compared with the normal control group, the amplitude of S1-P50, the amplitude of S2-P50 and the difference of S1-S2 in autism group before treatment were significantly lower than those in normal control group (all P <0.01). The latency of S1-P50 and S2- Significant difference (P> 0.05). There was no significant change in the latency and amplitude of S1-P50 and S2-P50 in autism group after 20 wk treatment compared with before treatment (P> 0.05). Conclusion The change of P50 may be one of the specific biological indicators of children with autism.